Ruixia Sun

Ruixia Sun

Auto-generated profile, based on publicly available information

Ruixia Sun

Department of Endocrinology and Metabolism, the Affiliated Hospital of Qingdao University, Qingdao, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
NLNan Liang
Nan Liang
MSMingshu Sun
Mingshu Sun
RSRuixia Sun
Ruixia Sun
TXTing Xu
Ting Xu
LCLingling Cui
Lingling Cui
CLChanggui Li
Changgui Li
Low doses of febuxostat or benzbromarone are widely used in Asian countries, but lacking studies to compare the efficacy and safety of the two urate-lowering drugs. To compare the efficacy and safety of low-dose febuxostat with low-dose benzbromarone in patients with primary gout, a randomized controlled, open-label trial was performed among male patients with primary gout for urate-lowering therapy (ULT) in a dedicated gout clinic in China. Randomization was carried out by a third-party institution according to random number table. Patients were randomly assigned 1:1 to febuxostat group (Feb group) (20 mg daily) or benzbromarone group (Ben group) (25 mg daily) and treated for 12 weeks. General information and biochemical data were collected at baseline and at every visit monthly. Clinical characteristics before and after the ULT were analyzed in the two groups by SPSS and EmpowerStats software. Two hundred forty patients were enrolled and randomized in the two groups, with 214 patients completing 12 weeks’ ULT (105 in the Feb group and 109 in the Ben group). After 12 weeks, substantial percentages of patients in both Feb and Ben group achieved the target serum uric acid (sUA) (< 360 μmol/L) and serum urate levels were reduced significantly for both groups (Feb 39.5% and 156.83 μmol/L vs. Ben 35.7% and 163.99 μmol/L). Multivariate analysis suggests baseline sUA level and renal function were associated with the outcome of the rate of achieving target sUA (RAT). Sub-group analysis suggests low doses of febuxostat and benzbromarone rendered better RAT for patients with sUA < 540 μmol/L and creatinine clearance rate (Ccr) ≤ 110 mL min−1 1.73 m−2 at baseline. The drugs were well tolerated, and the incidence of gout flares in Feb group was similar with that in Ben group (22.85% vs. 33.94%). Overall, febuxostat 20 mg daily and benzbromarone 25 mg daily reduced sUA, and gout patients with sUA level < 540 μmol/L or Ccr ≤ 110 mL min−1 1.73 m−2 at baseline had better chance to achieve target uric acid levels. The current study suggests sUA level and renal function are key factors to consider when recommending low doses of febuxostat and benzbromarone to gout patients. Registered with ChiCTR, No. ChiCTR1800019352 (retrospectively registered).

22 September 2020 in Aging
Verified
Journal Article
Open access
XCXiaoyu Cheng
Xiaoyu Cheng
TLTian Liu
Tian Liu
LMLidan Ma
Lidan Ma
ZLZhen Liu
Zhen Liu
YXYing Xin
Ying Xin
RSRuixia Sun
Ruixia Sun
Serum uric acid is reportedly associated with thrombosis development. However, still unclear is the mechanism of high uric acid in thrombosis with the involvement of let-7c. In an aim to fill this void, we conducted this study by treating mice and human umbilical vein endothelial cells with high uric acid. Analysis indicated that let-7c was upregulated in hyperuricemia patients as well as in mice and human umbilical vein endothelial cells treated with high uric acid. Furthermore, high uric acid inhibited myocyte enhancer factor-2C, but activated nuclear factor-kappa B pathway in human umbilical vein endothelial cells. Then the targeting relationship between let-7c and myocyte enhancer factor-2C was verified. On the one hand, high uric acid shortened activated partial thromboplastin time and prothrombin time of mice and declined tissue plasminogen activator level. Additionally, the treatment prolonged thrombin time and elevated the levels of thrombosis related molecules or proteins such as Fibrinogen and D-dimer. Nevertheless, these alternations could be reversed by inhibition of let-7c and nuclear factor-kappa B pathway or overexpressing myocyte enhancer factor-2C. To sum up, our results uncovered the pro-thrombotic effect of high uric acid in mice by activating myocyte enhancer factor-2C-dependent nuclear factor-kappa B pathway via let-7c upregulation.

17 August 2011 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
CCCaixia Cao
Caixia Cao
XYXuecheng Yang
Xuecheng Yang
Li LiLi Li
Li Li
RSRuixia Sun
Ruixia Sun
YXYuxin Xian
Yuxin Xian
YGYanyan Gao
Yanyan Gao

15 January 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
ZCZhaoying Chen
Zhaoying Chen
CJChen Jiang
Chen Jiang
XCXiaoyu Cheng
Xiaoyu Cheng
LMLidan Ma
Lidan Ma
YXYing Xin
Ying Xin
RSRuixia Sun
Ruixia Sun
Background: Previous reports have described hypogonadism associated with virus infection such as hantavirus, human immunodeficiency virus (HIV) or severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). However, to our best knowledge there has been no case report of secondary hypogonadism following hand, foot, and mouth disease (HFMD). Case presentation: A previously healthy 28-year-old man with no history of major physical and psychological trauma, presented with bilateral gynecomastia and erectile dysfunction 2 weeks after HFMD. Laboratory testament showed the level of gonadotropin hormones declined. Imaging examination demonstrated no major abnormal change in pituitary or reproductive system. The diagnosis of hypogonadism was established. Then the patient was ordered to maintain mental health outward of hospital without drug intervention. One month after presentation, his gonadotropin hormone level and sexual desire had recovered, while bilateral gynecomastia and erectile dysfunction symptoms disappeared. Conclusions: Physicians should notice the possibility for hypogonadism in adult patients with a recent history of HFMD.

26 March 2022 in International Urology and Nephrology
Verified
Journal Article
Closed access
PDF file
JZJie Zhang
Jie Zhang
MYMin Yang
Min Yang
XCXiaoyu Cheng
Xiaoyu Cheng
FQFei Qin
Fei Qin
SZShizhe Zhou
Shizhe Zhou
YCYing Chen
Ying Chen